Research Article| Volume 19, ISSUE 1, P96-112, January 1997

Cost-effectiveness of long-term intrathecal morphine therapy for pain associated with failed back surgery syndrome

      This paper is only available as a PDF. To read, Please Download here.


      A decision analytic study was conducted using computer simulation to project the outcomes in a simulated cohort of patients whose treatment for back surgery had failed. The objective of this study was to estimate the direct cost of intrathecal morphine therapy (IMT) delivered via an implantable pump relative to alternative therapy (medical management) over a 60-month course of treatment. IMT administered by way of an implantable pump can provide effective pain relief for selected patients whose less invasive treatment modalities have failed. Previous research suggested that a pump implant is less costly than alternative methods providing comparable analgesia for treatment exceeding 12 to 18 months. However, those analyses did not include the cost of complications or pump replacement. Scenarios representing the course of IMT, devised by a panel of experts, were represented as treatment pathways in a Monte Carlo simulation. Adverse event rates were drawn from published data supplemented by expert judgment. Direct costs were based on a health insurer paid claims perspective (direct costs) discounted at a 5% annual rate. The cost-effectiveness of IMT was calculated based on a report of 65% to 81% “good to excellent” pain relief relative to alternative (medical) management. With both adverse event probabilities and costs set at most likely (base case) values, the expected total cost of IMT over 60 months was $82,893 (an average of $1382 per month). In a sensitivity analysis, the best case (low adverse event rate, low cost) estimate was $53,468 ($891/mo), whereas the worst case (high adverse event rate, high cost) estimate was $125,102 ($2085/mo). Cost-effectiveness estimates ranged from $7212 (best case) to $12,276 (worst case) per year of pain relief. Results from a computer simulation designed to collect the costs not included in previous empiric research indicate that IMT appears to be cost-effective when compared with alternative (medical) management for selected patients when the duration of therapy exceeds 12 to 22 months


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Leitman R
        • Binns K
        • Unni A
        National Pain Survey (Study No. 942004). Louis Harris and Associates, New York1994
        • Frymoyer JW
        • Cats-Baril WL
        An overview of the incidences and costs of low back pain.
        Orthop Clin North Am. 1991; 22: 263-271
      1. National Center for Health Statistics.
        National Hospital Discharge Survey. US Department of Health and Human Services, Centers for Disease Control, Washington, DC1990 (Report no. PB 92-500818)
        • Bedder MD
        • Burchiel K
        • Larson A
        Cost analysis of two implantable narcotic delivery systems.
        J Pain Symptom Manage. 1991; 6: 368-373
        • Hillman AL
        • Eisenberg JM
        • Pauly MV
        • et al.
        Avoiding bias in the conduct of and reporting of cost-effectiveness research sponsored by pharmaceutical companies.
        NEJM. 1991; 324: 1362-1365
      2. Merskey H Bogduk N Task Force on Taxonomy of the International Association for the Study of Pain: Classification of Chronic Pain. IASP Press, Seattle1994
        • Paice JA
        • Magolan JM
        Intraspinal drug therapy.
        Nurs Clin North Am. 1991; 26: 477-498
        • Krames ES
        Intrathecal infusional therapies for intractable pain: Patient management guidelines.
        J Pain Symptom Manage. 1993; 9: 36-46
        • Krames ES
        • Lanning RM
        Intrathecal infusional analgesia for nonmalignant pain: Analgesic efficacy of intrathecal opioid with or without bupivacaine.
        J Pain Symptom Manage. 1993; 3: 539-548
        • Paice JA
        • Penn RD
        • Ryan WG
        Altered sexual function and decreased testosterone in patients receiving intraspinal opioids.
        J Pain Symptom Manage. 1994; 9: 126-131
        • Hassenbusch SJ
        • Pillay PK
        • Magdinec M
        • et al.
        Constant infusion of morphine for intractable cancer pain using an implanted pump.
        J Neurosurg. 1990; 73: 405-409
      3. (Data on file)
        • Paice JA
        • Penn RD
        • Shott S
        Intrathecal morphine for chronic pain: A retrospective, multi-center study. Department of Neurosurgery, Rush Medical Center, Chicago, Illinois1994
        • Medtronic, Inc.
        Neurological Division. Returned Product Analysis. 1994; (Data on file) (Minneapolis, Minnesota)
      4. (Data on file)
        • Hassenbusch SJ
        • Payne R
        • Paice JA
        • et al.
        Charge modeling of opioid therapy via different delivery routes for cancer pain management. Department of Neurosurgery, University of Texas, M.D. Anderson Cancer Center, Houston, Texas1994 (Report by)
      5. Physician Payment Review Commission. Annual Report to Congress: 1994. Washington, DC. 1995; (Physician Payment Review Commission)
      6. Red Book. 1994 Drug Topics. Medical Economics Publishing Co, Montvale, NJ1994
        • Ferrell BR
        • Griffith H
        Cost issues related to pain management: Report from the cancer pain panel of the Agency for Health Care Policy and Research.
        J Pain Symptom Manage. 1994; 9: 221-234
        • Turk DC
        • Rudy TE
        • Sorkin BA
        Neglected topics in chronic pain treatment outcome studies: Determination of success.
        Pain. 1993; 53: 3-16
        • North RB
        • Campbell JN
        • James CS
        • et al.
        Failed back surgery syndrome: 5-year follow-up in 102 patients undergoing repeated operation.
        Neurosurgery. 1991; 28: 685-691
        • Loeser JD
        • Bigos SJ
        • Fordyce WE
        • Volinn EP
        Low back pain.
        in: Bonica JJ The Management of Pain. Lea & Febiger, Philadelphia1990: 1472
      7. Current Procedural Terminology. American Medical Association, Chicago1995
        • Graham AA
        • Holohan TV
        External and implantable infusion pumps.
        Health Technology Review 7. US Department of Health and Human Services, Agency for Health Care Policy and Research, Rockville, Md1993
        • Agency for Health Care Policy and Research (AHCPR)
        Management of cancer pain: Adults.
        Practice Guidelines Quick Reference Guide for Clinicians No. 9. US Department of Health and Human Services, Public Health Service, Rockville Md1994
        • Auld AW
        • Maki-Jokela A
        • Murdoch DM
        Intraspinal narcotic analgesia in the treatment of chronic pain.
        Spine. 1985; 10: 779-781
        • Cousins MJ
        • Plummer JL
        Spinal opioids in acute and chronic pain.
        in: Max MB Portenoy RK Laska EM Advances in Pain Research and Therapy. The Design of Analgesic Clinical Trials. 18. Raven Press, New York1991: 457-479
        • Talo S
        • Puukka P
        • Rytokoski U
        • et al.
        Can treatment outcome of chronic low back pain be predicted? Psychological disease consequences clarifying the issue.
        Clin J Pain. 1994; 10: 107-121
        • Brose WG
        Health outcomes.
        Clin J Pain. 1994; 10 (Editorial): 89-94
        • Deyo RA
        Low back pain.
        Adv Pain Res Ther. 1991; 18: 291-303